ZNAČAJ FARMAKOGENETIKE U TERAPIJSKOJ PRIMENI KLOPIDOGRELA
Sažetak
Cerebrovaskularna i kardiovaskularna oboljenja su jedan od vodećih uzroka smrti širom sveta. Samim tim, njihova terapija ima veliki značaj. Važno mesto u terapiji zauzima klopidogrel, samostalno ili u kombinaciji sa aspirinom. Problem koji se javlja u lečenju jeste slabiji odgovor na standardnu terapiju, a time i povećana stopa ponovnih kardiovaskularnih događaja. Ovaj slabiji odgovor na terapiju klopidogrelom posledica je pre svega farmakogenomske modifikacije enzima citohroma P450, kao i P-glikoproteina odgovornih za apsorpciju i bioraspoloživost. Kod pacijenata koji pokazuju slabiji odgovor na standardnu antiagregacionu terapiju preporučuje se genetsko testiranje.
Reference
Ilić S. Akutni koronarni sindrom. U: Ilić S, Lović B, Marković V, urednici. Interna medicina, Knjiga II. Niš: Prosveta, 2004: 48-54.
Kažić T, Ostojić M, urednici. Klinička kardiovaskularna farmakologija. Beograd: Integra, 2009.
Anderson CD, Biffi A, Greenberg SM, Rosand J. Personalized approaches to clopidogrel therapy: are we there yet? Stroke 2010; 41(12): 2997-3002.
American Society of Health-system Pharmacists. AHFS Drug information. Bethesada: Maryland, 2011.
Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001; 86(1): 22-32.
Di Girolamo G, Czerniuk P, Bertuola R, Keller GA. Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. Clin Ther 2010; 32(1): 161-70.
Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005; 31(2): 174-83.
Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108(7): 2244-7.
Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38(1): 92-9.
Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 2010; 50(2): 126-42.
Giorgi MA, Di Girolamo G, González CD. Nonresponders to clopidogrel: pharmacokinetics and interactions involved. Expert Opin Pharmacother 2010; 11(14): 2391-403.
Slugg PH, Much DR, Smith WB, Vargas R, Nichola P, Necciari J. Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel. J Clin Pharmacol 2000; 40(4): 396-401.
McEwen J, Strauch G, Perles P, et al. Clopidogrel bioavailability: Absence of influence of food or antacids. Semin Thromb Hemost 1999; 25 Suppl 2: 47-50.
Ma TK, Lam YY, Tan VP, Kiernan TJ, Yan BP. Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel. Pharmacol Ther 2010; 125(2): 249-59.
Taubert D, Kastrati A, Harlfinger S, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004; 92(2): 311-6.
von Beckerath N, Taubert D, Pogatsa-Murray G, Schömig E, Kastrati A, Schömig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Chosen between 3 high oral doses for immediate Clopidogrel effect) Trial. Circulation 2005; 112(19): 2946-50.
Mullangi R, Srinivas NR. Clopidogrel: Review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug-drug interaction studies. Biomed Chromatogr 2009; 23(1): 26-41.
Second Chinese Cardiac Study Collaborative group. A randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. J Cardiovasc risk 2000; 7(6): 435-41.
Diener HC, Ringleb PA, Savi P. Clopidogrel for the secondary prevention of stroke. Expert Opin Pharmacother 2005; 6(5): 755-64.
Fox KA, Chelliah R. Clopidogrel: An updated and comprehensive review. Expert Opin Drug Metab Toxicol 2007; 3(4): 621-31.
Varenhorst C, James S, Erlinge D, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 2009; 30(14): 1744-52.
Gladding P, Webster M, Zeng I, et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv 2008; 1(6): 620-7.
Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: A review of the evidence. J Am Coll Cardiol 2005; 45(8): 1157-64.
Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. Thromb Haemost 2010; 103(4): 841-8.
Combescure C, Fontana P, Mallouk N, et al. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2010; 8(5): 923-33.
Djukanovic N, Todorovic Z, Grdinic A, Prostran M, Ostojic M. Thienopyridine resistance among patients undergoing intracoronary stent implantation and treated with dual antiplatelet therapy: assessment of some modifying factors. J Pharmacol Sci 2008; 107(4): 451-5.
Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006; 27(6): 647-54.
Ernesto O, Martin H, Ronald D. Clopidogrel resistance. Heart Lung Circ 2007; 16(3): S17-28.
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49(14): 1505-16.
Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45(2): 246-51.
Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107(23): 2908-13.
Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89(5): 783-7.
Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007: 5(12): 2429-36.
Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373(9660): 309-17.
Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006; 174(12): 1715-22.
Fontana P, Hulot JS, De Moerloose P, Gaussem P. Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J Thromb Haemost 2007; 5(10): 2153-5.
Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302(8): 849-57.
Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41(12): 913-58.
Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008; 84(2): 236-42.
Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815-50.
Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006; 80(5): 486-501.
Geisler T, Anders N, Paterok M, et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007; 30(2): 372-4.
Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function morphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108(7): 2244-7.
Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360(4): 354-62.
Ellis KJ, Stouffer GA, McLeod HL, Lee CR. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics 2009; 10(11): 1799-817.
Pinto Slottow TL, Bonello L, Gavini R, et al. Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. Am J Cardiol 2009; 104(4): 525-30.
Djukanović N, Todorović Z, Njegomirović S, Ostojić M, Prostran M. Advantages and limitations of clopidogrel response testing methods. Vojnosanit Pregl 2012; 69(4): 353-7.
Stegnar M. Platelet function tests and resistance to antiplatelet therapy. Srp Arh Celok Lek 2010; 138(Suppl 1): 59-63.
Gurbel PA, Cummings CC, Bell CR, et al. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction of New Thrombus Occurrence (PRONTO) trial. Am Heart J 2003; 145(2): 239-47.
Serebruany VL, Midei MG, Malinin AI, et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med 2004; 164(18): 2051-7.
Vinholt P, Poulsen TS, Korsholm L, et al. The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. Thromb Haemost 2005; 94(2): 438-43.
Saw J, Brennan DM, Steinhubl SR, et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 2007; 50(4): 291-5.
Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007; 81(5): 735-41.
Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 2005; 77(6): 553-9.
Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51(3): 256-60.
Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52(18): 1502-17.
Aubert RE, Epstein RS, Teagarden JR, et al. Proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel Medco outcomes study. Circulation 2008; 118: S_815.
Steinhubl SR, Berger PB, Brennan DM, Topol EJ; CREDO Investigators. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006; 47(5): 939-43.
von Beckerath N, von Beckerath O, Koch W, Eichinger M, Schömig A, Kastrati A. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis 2005; 16(3): 199-204.
Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111(25): 3366-73.
Unger E. Weighing Benefits and Risks - The FDA’s Review of Prasugrel. N Engl J Med 2009; 361(10): 942-5.
Cannon CP. Clopidogrel: to test or not to test? That is the question--still. Clin Chem 2011; 57(5): 659-61.
Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga Creative Commons licencom koja omogućava drugima da dele rad uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.
Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju rada objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je rad izvorno objavljen u ovom časopisu.
Autorima je dozvoljeno i podstiču se da postave objavljeni rad onlajn (npr. u institucionalnom repozitorijumu ili na svojim internet stranicama) pre i tokom postupka prijave priloga, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog rada (up. Efekat otvorenog pristupa).